Modificación del hR3 con DOTA-NHS. Marcaje con 90Y y biodistribución

abstract the conjugation, characterization and biodistribution of -dota-hr3 radioimmunoconjugate are reported in this work. dota was used as bifunctional chelating agent. molar ratios 320:1, 160:1 and 88:1 dota/monoclonal antibody hr3 were studied in order to evaluate their influence on the integrity of conjugate and labeling efficiency. in vivo stability of -dota-hr3 radioimmunoconjugates was determined in healthy wistar rats at 4, 24 and 48 h after the injection. stability studies performed by means of dtpa challenge showed that the compound is stable in a wide period of time (up to 216 h). in vivo stability studies, based on the bone uptake, showed that the radiometal release from the radioimmunoconjugate is not significant in the first 48 hours.